PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3902 trials with phase data)• Click on a phase to view related trials
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
- Conditions
- COVID-19
- Interventions
- Drug: nirmatrelvir-ritonavir
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14000
- Registration Number
- NCT07090486
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Conditions
- Advanced/Metastatic Solid TumorsBladder CancerUrothelial CarcinomaAdvanced Non-Small Cell Lung CancerCarcinoma, Non Small Cell LungCarcinoma, Squamous Cell of Head and NeckHead and Neck CancerEsophageal CancerGastroesophageal Junction AdenocarcinomaEsophageal Squamous Cell Carcinoma
- Interventions
- Drug: PF-08046876
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 310
- Registration Number
- NCT07090499
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1200
- Registration Number
- NCT07089680
A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT07086664
- Locations
- 🇺🇸
Javara - Nevada Health Centers - Carson City, Carson City, Nevada, United States
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate NeoplasmsProstate Cancer
- Interventions
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1300
- Registration Number
- NCT07086651
- Prev
- 1
- 2
- 3
- 4
- 5
- 637
- Next
News
Basilea Launches Phase 3 Trial for Novel Antifungal Fosmanogepix in Invasive Mold Infections
Basilea Pharmaceutica has initiated FORWARD-IM, a phase 3 registrational study evaluating fosmanogepix for treating invasive mold infections in adults, with completion expected in Q1 2028.
Ivonescimab Demonstrates Superior Efficacy in Phase III Lung Cancer Trials, Positioning for Global Regulatory Approvals
Ivonescimab, a PD-1/VEGF bispecific antibody, achieved a 48% reduction in progression-free survival risk compared to chemotherapy in EGFR-mutated NSCLC patients.
Comprehensive Pipeline Analysis Reveals 200+ Investigational Drugs for Metastatic Hormone Refractory Prostate Cancer
A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
EU Regulatory Approval Advances Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for 2025-2026 Season
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.
Roche Explores Direct-to-Consumer Drug Sales Model to Reduce US Patient Costs
Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.
RedHill Biopharma Receives FDA Approval for Groundbreaking MAP-Targeted Crohn's Disease Study
RedHill Biopharma received positive FDA feedback for the first-ever clinical study targeting Mycobacterium avium subspecies paratuberculosis (MAP) infected Crohn's disease patients with RHB-204.
Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes
A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
Bristol Myers Squibb and Pfizer Launch Direct-to-Patient Eliquis Program with 40% Price Discount
Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.